Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Acquires 38,880 Shares of Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. acquired 38,880 shares of Oncocyte stock in a transaction that occurred on Friday, April 24th. The shares were bought at an average price of $3.53 per share, with a total value of $137,246.40. Following the transaction, the insider directly owned 12,433,961 shares in the company, valued at approximately $43,891,882.33. This trade represents a 0.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 27th, Broadwood Partners, L.P. acquired 250,923 shares of Oncocyte stock. The shares were bought at an average price of $3.64 per share, with a total value of $913,359.72.
• On Thursday, April 23rd, Broadwood Partners, L.P. acquired 280,381 shares of Oncocyte stock. The shares were bought at an average price of $3.50 per share, with a total value of $981,333.50.
• On Monday, April 20th, Broadwood Partners, L.P. acquired 40,690 shares of Oncocyte stock. The shares were bought at an average price of $3.88 per share, with a total value of $157,877.20.
• On Friday, April 17th, Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock. The shares were bought at an average price of $3.57 per share, with a total value of $143,206.98.
• On Thursday, April 16th, Broadwood Partners, L.P. acquired 102,057 shares of Oncocyte stock. The shares were bought at an average price of $3.45 per share, with a total value of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. bought 521,739 shares of Oncocyte stock. The stock was purchased at an average price of $5.75 per share, with a total value of $2,999,999.25.

Oncocyte Trading Up 2.1%

NASDAQ IMDX opened at $3.84 on Tuesday. Oncocyte Corp has a 52 week low of $2.33 and a 52 week high of $8.51. The company has a market cap of $123.53 million, a PE ratio of -2.37 and a beta of 1.52. The stock has a 50-day moving average price of $4.34.

Oncocyte (NASDAQ:IMDX) last posted its earnings results on Thursday, March 26th. The company reported ($0.27) EPS for the quarter. The business had revenue of $1.14 million for the quarter.

Analyst Ratings Changes

A number of research analysts have issued reports on IMDX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a research report on Friday, March 27th. Wall Street Zen lowered Oncocyte from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Lake Street Capital boosted their price target on Oncocyte from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Oncocyte currently has an average rating of “Hold” and an average price target of $12.00.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.